The Risk Evaluation and Mitigation Strategy piece of the FDA Amendments Act of 2007 , aka REMS, was a hot topic at the Task Force meeting last month. While it seems there may be a few wrinkles to work out, our columnist Stephen Lewis thinks it might end up being an area of opportunity for CME providers; others I spoke with weren't so sure we could get past some of the potential conflicts they could involve. Here's a YouTube video he posted recently about REMS:
What do you think? Are the issues insurmountable, or will REMS become part of the CME provider repertoire?